Cargando…
晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展
Targeted therapy was one of the major treatments in advanced non-small cell lung cancer (NSCLC) with positive driver genes. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers have also undergone dee...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973289/ https://www.ncbi.nlm.nih.gov/pubmed/28103976 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.01.10 |
Ejemplares similares
-
驱动基因阳性肺癌脑转移患者的靶向治疗进展
Publicado: (2019) -
非小细胞肺癌驱动基因突变及靶向治疗的研究进展
Publicado: (2014) -
晚期非小细胞肺癌HER2基因突变靶向治疗进展
Publicado: (2020) -
驱动基因阳性非小细胞肺癌免疫治疗进展
Publicado: (2022) -
ALK融合基因阳性非小细胞肺癌的研究进展
Publicado: (2018)